NOVT Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.…
Industry Peers
Scientific & Technical InstrumentsKey Statistics
About Novanta (NASDAQ: NOVT)
›
Novanta (NASDAQ: NOVT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Scientific & Technical Instruments industry, part of the Technology sector, and reports about 3,000 employees.
The shares were at 114.88 USD on 19 November 2026, up 7.1% over 52 weeks. Its 52-week range is 98.27 USD to 176.19 USD: the price is 34.8% below the high and 16.9% above the low.
At a market capitalisation of 4.34B USD, it trades at 87.0 times trailing earnings and 26.9 times forward earnings. The median trailing P/E of its 19 largest Scientific & Technical Instruments peers is 30.2, a premium of 188% for NOVT.
Novanta reports return on equity of 4.1%, an operating margin of 11.8% and revenue up 23.1% year over year.
Its debt exceeds its cash by 744.92M USD, a debt-to-equity ratio of 0.23. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 185.00 USD is 61.0% above the current price. The next earnings report is expected on 23 February 2027.